HUGE
Income statement / Annual
Last year (2023), FSD Pharma Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, FSD Pharma Inc.'s net income was -$18.56 M.
See FSD Pharma Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
08/31/2016 |
08/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$196,819.00 |
$65,169.00 |
$20,630.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$2.55 M
|
$4.36 M
|
$4.01 M
|
$4.11 M
|
$2.04 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$2.55 M
|
-$4.36 M
|
-$4.01 M
|
-$4.11 M
|
-$1.84 M
|
$65,169.00
|
$20,630.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
-9.36
|
1
|
1
|
0
|
0
|
| Research and Development Expenses |
$3.93 M
|
$6.91 M
|
$6.33 M
|
$7.83 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$11.97 M
|
$15.98 M
|
$23.37 M
|
$18.11 M
|
$22.86 M
|
$16.13 M
|
$2.82 M
|
$29,628.00
|
$32,800.00
|
| Selling & Marketing Expenses |
$13.43 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.06 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.45 M
|
$15.98 M
|
$23.37 M
|
$18.11 M
|
$22.86 M
|
$18.19 M
|
$2.82 M
|
$29,628.00
|
$32,800.00
|
| Other Expenses |
$0.00
|
$4.54 M
|
$4.05 M
|
$4.66 M
|
$3.12 M
|
-$401,897.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$17.38 M
|
$27.43 M
|
$33.74 M
|
$30.60 M
|
$25.98 M
|
$18.62 M
|
$2.82 M
|
$29,628.00
|
$32,800.00
|
| Cost And Expenses |
$19.93 M
|
$27.43 M
|
$33.74 M
|
$30.60 M
|
$28.02 M
|
$18.62 M
|
$2.82 M
|
$29,628.00
|
$32,800.00
|
| Interest Income |
$800,783.00
|
$367,735.00
|
$1,292.00
|
$3,691.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$304.48
|
$48,822.00
|
$69,404.00
|
$235,581.00
|
$158,048.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$2.55 M
|
$4.53 M
|
$4.05 M
|
$3.90 M
|
$2.41 M
|
$134,500.00
|
$52,516.00
|
$22,816.00
|
$0.00
|
| EBITDA |
-$17.38 M |
-$22.41 M |
-$29.65 M |
-$26.02 M |
-$25.34 M |
-$20.31 M |
-$2.80 M |
-$29,628.67 |
-$32,800.43 |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
-128.72
|
-311.58
|
-135.86
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
-142.63
|
-313.64
|
-135.86
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.36 M
|
$725,949.00
|
-$194,296.00
|
$2.24 M
|
-$11.75 M
|
$1.88 M
|
$0.00
|
$0.00
|
$0.00
|
| Income Before Tax |
-$18.56 M
|
-$26.70 M
|
-$33.94 M
|
-$28.45 M
|
-$39.82 M
|
-$16.67 M
|
-$2.80 M
|
-$29,628.67
|
-$32,800.43
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
-202.31
|
-255.86
|
-135.86
|
0
|
0
|
| Income Tax Expense |
-$1.00
|
-$3.38 M
|
$1.47 M
|
$4.27 M
|
$235,158.00
|
-$3.77 M
|
-$52,516.00
|
-$22,816.00
|
$0.00
|
| Net Income |
-$18.56 M
|
-$23.32 M
|
-$35.41 M
|
-$32.72 M
|
-$40.05 M
|
-$16.67 M
|
-$2.80 M
|
-$29,628.67
|
-$32,800.43
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
-203.5
|
-255.86
|
-135.86
|
0
|
0
|
| EPS |
-0.47 |
-0.6 |
-1.01 |
-2.72 |
-5.68 |
-2.82 |
-0.43 |
-0.0045 |
-0.005 |
| EPS Diluted |
-0.47 |
-0.6 |
-1.01 |
-2.72 |
-5.68 |
-2.82 |
-0.43 |
-0.0045 |
-0.005 |
| Weighted Average Shares Out |
$39.59 M
|
$38.73 M
|
$34.95 M
|
$12.04 M
|
$7.06 M
|
$5.91 M
|
$6.57 M
|
$6.57 M
|
$6.57 M
|
| Weighted Average Shares Out Diluted |
$39.59 M
|
$38.73 M
|
$34.95 M
|
$12.04 M
|
$7.06 M
|
$5.91 M
|
$6.57 M
|
$6.57 M
|
$6.57 M
|
| Link |
|
|
|
|
|
|
|
|
|
